C-64 , 44th Parliament, 1st session November 22, 2021, to present

An Act respecting pharmacare
Short title: Pharmacare Act
Bill type
House Government Bill


Current status
At second reading in the House of Commons
Latest activity
Introduction and first reading on February 29, 2024 (House of Commons)


End of stage activity
Introduction and first reading, February 29, 2024
Chamber sittings
Sitting date Debates (Hansard)
February 29, 2024
Second reading
No activity
Consideration in committee
Not reached
Report stage
Not reached
Third reading
Not reached


First reading
Not reached
Second reading
Not reached
Third reading
Not reached


Recorded votes

House of Commons

There are currently no recorded votes for this bill.


To view the complete list of standing votes that have taken place in the Senate, please refer to the Votes page of the Senate of Canada website.

Speaker's rulings and statements

There are currently no Speaker's rulings and statements.

Major speeches at second reading

There are currently no major speeches for this bill.


Legislative summary

A legislative summary is currently being prepared for this bill by the Parliamentary Information, Education and Research Services of the Library of Parliament. Meanwhile, the following executive summary is available.

On 29 February 2024, the Minister of Health introduced Bill C-64, An Act respecting pharmacare (Pharmacare Act), and it was given first reading.

Bill C-64 sets out the principles that the Minister of Health is to consider when working towards the implementation of national universal pharmacare and provides the Minister with the power to make payments, in certain circumstances, in relation to the coverage of certain prescription drugs and related products. It also sets out certain powers and obligations of the Minister — including in relation to the preparation of a list to inform the development of a national formulary and in relation to the development of a national bulk purchasing strategy — and requires the Minister to publish a pan-Canadian strategy regarding the appropriate use of prescription drugs and related products. Finally, it provides for the establishment of a committee of experts to make certain recommendations.
Export as: JSON XML

For more data options, please see Open Data

Top of page